Posted on:
Mar 30, 2022 07:55PM
O
Joined:
Dec 2021
Posts:
30
Latest activity:
Aug 13, 2022
Posted on:
Mar 30, 2022 07:55PM
odyssey305
wrote:
Hi everyone. Before I call Genomic Health with this, I thought I would check with the wise people on BCO…what is the significance of the ER/PR scores reported on the Oncotype report other than confirming + or - receptor status? Also what is the range for strongly positive, moderately positive etc? I’ve tried to find some information online and came across a similar thread on this board, but I’m still stumped. I’m midway through treatment so this won’t necessarily impact any decisions for me, but I am really curious and maybe others are too as there’s so little information. Thank you!
Dx
12/2021, IDC, Right, 1cm, Stage IB, Grade 1, 1/5 nodes, ER+/PR+, HER2-, FISHISHCISH
Surgery
1/1/2022 Lumpectomy (Right); Lymph node removal (Right): Sentinel
Surgery
1/29/2022 Lumpectomy; Lumpectomy (Right); Lymph node removal
Hormonal Therapy
2/1/2022
Radiation Therapy
3/3/2022 Whole breast: Right breast
Surgery
4/1/2022
Surgery
Radiation Therapy
Whole breast: Breast, Lymph nodes
Hormonal Therapy
Femara (letrozole), Zoladex (goserelin)
Hormonal Therapy
Log in to post a reply
M
moth
BC
Joined:
Dec 2017
Posts:
4,761
Latest activity:
Aug 3, 2022
Log in to post a reply
Mar 30, 2022 08:06PM
moth
wrote:
Oncotype uses a different method to determine hormone status than IHC. It is said that if there's a discrepancy, you should go with the IHC. But, in some cases - like mine - it leads to a whole review of IHC status. My 2017 initial IHC from biopsy was 10% faint ER+/PR-/HER2-. Oncotype came back & said I was triple neg. My biopsy sample & my tumor sample did the rounds among pathologists here for 2nd opinions & eventually they coded it as negative as well.
I believe Oncotype factors the strength of the ER positivity into the recurrence score. Not sure how well the search function is doing right now but Beesie did a number of posts about this .. I think she's on board break while the board is being revamped atm
I take weekends off Initial dx at 50. Seriously?? “Sometimes the future changes quickly and completely and we’re left with only the choice of what to do next." blog: Never Tell Me the Odds
Dx
12/2017, IDC, Left, 1cm, Stage IA, Grade 3, 0/5 nodes, ER-/PR-, HER2-
Surgery
12/12/2017 Lumpectomy; Lumpectomy (Left); Lymph node removal
Chemotherapy
2/14/2018 AC + T (Taxol)
Radiation Therapy
8/13/2018 Whole breast: Breast
Dx
2/2020, IDC, Left, Stage IV, metastasized to liver/lungs, Grade 3, ER-/PR-, HER2-
Chemotherapy
3/18/2020 Taxol (paclitaxel)
Immunotherapy
3/18/2020 Tecentriq (atezolizumab)
Chemotherapy
11/25/2020 Abraxane (albumin-bound or nab-paclitaxel)
Radiation Therapy
12/9/2020 External
Hormonal Therapy
12/15/2020 Femara (letrozole)
Radiation Therapy
3/3/2021 External
Local Metastases
3/3/2021 Radiation therapy: Bone
Targeted Therapy
1/1/2022 Trodelvy (sacituzumab govitecan-hziy)
Chemotherapy
6/1/2022 Other
O
odyssey305
Joined:
Dec 2021
Posts:
30
Latest activity:
Aug 13, 2022
Log in to post a reply
Apr 2, 2022 12:19PM
- edited
Apr 2, 2022 12:22PM
by
odyssey305
Hi Moth! That was my next question, about discrepancies - thank you for clearing that up for me. I'm sorry to hear about what you went through, I'm sure all the waiting was nerve-wracking. My initial biopsy report showed that I was strongly ER/PR positive but my Oncotype showed that I was only moderately ER+ and weakly PR+ (if I understood the scores correctly). My MO didn't seem concerned and I didn’ think to ask at the time.Now I'm curious about whether discrepancies are due to tumor heterogeneity or if the Oncotype testing is more sensitive. I'll see if I can pull up Bessie's posts about this…
Hope you have a peaceful weekend😊
Dx
12/2021, IDC, Right, 1cm, Stage IB, Grade 1, 1/5 nodes, ER+/PR+, HER2-, FISHISHCISH
Surgery
1/1/2022 Lumpectomy (Right); Lymph node removal (Right): Sentinel
Surgery
1/29/2022 Lumpectomy; Lumpectomy (Right); Lymph node removal
Hormonal Therapy
2/1/2022
Radiation Therapy
3/3/2022 Whole breast: Right breast
Surgery
4/1/2022
Surgery
Radiation Therapy
Whole breast: Breast, Lymph nodes
Hormonal Therapy
Femara (letrozole), Zoladex (goserelin)
Hormonal Therapy
